Viking Crashes the Obesity Party

Welcome to LazyListen. This is The Daily Rip for today. S.

stocks delivered a mixed session Tuesday as a dip in crude oil prices eased inflation worries but couldn’t offset a sharp selloff in the banking sector. The Nasdaq hit a fresh record high, small caps advanced, while the Dow slipped back below 52,000. Tech and biotech led the charge, fueled by strong momentum in artificial intelligence and obesity drug developments.

Starting with the big movers, Viking Therapeutics stole the spotlight after releasing impressive obesity drug data. Their dual GLP-1/GIP candidate, VK2735, showed weight loss between 16 and nineteen percent at 21 weeks, with an exploratory group hitting twenty two percent by week 33. Nearly all patients on the drug lost weight, compared to none on placebo.

This puts Viking in direct competition with Eli Lilly and Novo Nordisk, who have dominated the obesity treatment space with their GLP-1 drugs. Viking’s stock surged thirty six percent to over 40 dollars, marking its biggest one-day gain since early 2024. The market is buzzing because Viking’s oral and injectable options could shake up the duopoly, and that’s why buyout rumors keep swirling.

Roche also posted positive obesity data, adding to the sector’s excitement. Meanwhile, Micron extended its winning streak to four days, climbing five percent to just over 109 dollars. I.

demand ahead of its fiscal fourth-quarter earnings report next week. Analysts expect a massive jump in earnings per share, nearly tenfold from a year ago, with revenue forecasted to more than triple. Memory peers like SanDisk also rallied, confirming the strength of this cycle.

But with expectations sky-high, any disappointment in Micron’s report could trigger a selloff. On the flip side, Royal Caribbean’s stock dropped more than six percent after reports surfaced that it’s negotiating to buy a majority stake in Sandals Resorts for over six billion dollars. This would be Royal Caribbean’s largest acquisition ever, six times bigger than its previous biggest deal.

The move aims to build a combined land-and-sea vacation empire, as cruises only make up about two percent of global travel spending. However, investors are wary of the risks, especially since Royal Caribbean’s stock is down about twenty five percent over the past year amid softer European demand. The deal could be announced soon, but there’s still a chance talks fall apart.

In the ad-tech space, The Trade Desk officially dropped out of the S&P 500 and landed in the SmallCap 600 after a nearly ninety percent collapse from its peak last December. The stock fell five percent on Tuesday, closing just above its 52-week low. The company’s revenue growth slowed to three percent in quarter two, missing estimates, and it laid off over 500 employees.

Shareholders will soon vote on repricing underwater employee stock options, highlighting the tough 14 months the company has faced. This demotion is a clear sign of the challenges in digital advertising amid shifting budgets and economic uncertainty. Looking at other quick movers, BlackBerry gained about one percent after landing a design win for its Alloy Kore platform with a Daimler Truck and Volvo joint venture, signaling progress in commercial vehicle tech.

I. agent Muse integrated Shop Pay for checkout, enhancing the e-commerce platform’s reach. Lennar rose six percent after Berkshire Hathaway increased its stake to roughly ten percent, doubling down on housing despite a weaker market backdrop.

-driven storage demand. Amgen added four percent following positive Phase 3 trial results for a Sjögren’s disease drug, though more data is needed before approval. On the macro front, traders are eyeing tomorrow’s flash manufacturing and services purchasing managers indexes for September, which will provide early clues on economic momentum.

Fed Governor Michael Barr is also scheduled to speak, potentially offering insights on monetary policy. Earnings reports to watch include General Mills, Manchester United, Cracker Barrel, and Paychex before the open, with Stitch Fix reporting after the bell. I.

and biotech innovation and caution around big acquisitions and banking weakness. Viking’s obesity drug data and Micron’s chip cycle are driving sector leadership, while Royal Caribbean’s ambitious deal and The Trade Desk’s fall highlight ongoing risks. Tomorrow’s economic data and earnings will be key to setting the next direction.

Thanks for listening. Catch you next time on LazyListen.